

In the claims:

1. (currently amended) A method of treating BPH in a subject in need of such treatment which method comprises administering to said subject ~~an~~ a synergistically effective amount of a combination of (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) an α_1 -adrenergic receptor antagonist, or a pharmaceutically acceptable derivative salt or solvate thereof, wherein said α_1 -adrenergic receptor antagonist is selected from 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or a pharmaceutically acceptable salt or solvate thereof.

2. (original) The method of claim 1 wherein (A) and (B) are administered simultaneously, sequentially or separately.

Claims 3-4 (canceled)

5. (currently amended) The method of claim 3 1, wherein (B) is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative salt or solvate thereof.

6. (currently amended) The method of claim 3 1, wherein (B) is 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or a

pharmaceutically acceptable ~~derivative~~ salt or solvate thereof.

7. (canceled)

8. (currently amended) A pharmaceutical composition comprising synergistic amounts of (A) atorvastatin or a pharmaceutically acceptable ~~derivative~~ salt thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable ~~derivative~~ salt or solvate thereof.

9. (currently amended) A pharmaceutical composition comprising synergistic amounts of (A) atorvastatin or a pharmaceutically acceptable ~~derivative~~ salt or solvate thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable ~~derivative~~ salt or solvate thereof.

10. (canceled)

11. (currently amended) A pharmaceutical composition comprising, separately or together, synergistic amounts of (A) atorvastatin or a pharmaceutically acceptable ~~derivative~~ salt or solvate thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable ~~derivative~~ salt or solvate thereof, for simultaneous, sequential or separate administration in the treatment of BPH.

12. (currently amended) A pharmaceutical composition comprising, separately or together, synergistic amounts of (A) atorvastatin or a pharmaceutically acceptable derivative salt or solvate thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable derivative salt or solvate thereof, for simultaneous, sequential or separate administration in the treatment of BPH.

13. (currently amended) A pharmaceutical composition according to any one of claims ~~7-12~~ 8, 9, 11, or 12, further comprising a pharmaceutically acceptable carrier.